NEWS Collaborations between academia and industry play an important role in turning research into practical applications. Researcher Chinmay Dwibedi shared insights from his work with BioGaia AB during the recent Open up for Innovation event at Umeå University.
Chinmay Dwibedi is truly committed to ensuring that his research benefits society. He was one of the invited speakers at Open up for Innovation.
ImageTomas RuuthThe third edition of the conference Open up for Innovation gathered researchers, industry representatives and doctoral students to explore how collaborations across sectors can accelerate scientific progress and generate value for society. The event, organised by Umeå Biotech Incubator (UBI), brought together around 70 researchers and 30 participants from industry, creating a dynamic arena for matchmaking, inspiration and exchange of experiences.
One of the invited speakers was Chinmay Dwibedi, whose research focuses on understanding human gut microbes at high resolution. His group investigates how bacterial strains evolve, differ functionally and influence human health. The long-term aim is to pave the way for microbiome‑based therapies by identifying how specific microbes contribute to disease, health, and drug responses.
Chinmay Dwibedi highlighted his collaboration with the probiotic company BioGaia AB, describing the partnership as both constructive and eye-opening.
This real‑world perspective helps us put our academic findings into a more practical and translational context
“They are a science‑driven company with strong respect for evidence, and very open in sharing their knowledge on strains, manufacturing and efficacy. This real‑world perspective helps us put our academic findings into a more practical and translational context, he says.
Chinmay Dwibedi was recently awarded funding from the Industrial Doctoral School at Umeå University for a doctoral project in collaboration with BioGaia. He emphasised that academic–industry collaboration is essential for developing new probiotic concepts, including emerging ideas such as precision probiotics.
“It bridges discovery and application. What we see as exciting science may not always be feasible to translate into products because of cost, production or regulation. Industry brings valuable real‑world insight from clinicians and microbiologists, ensuring new concepts are both scientifically sound and practically relevant.”
Looking ahead, Chinmay Dwibedi sees major potential in personalised microbiome‑based therapies.
“These therapies are not one‑size‑fits‑all. A key opportunity is identifying which one benefits the most. With better clinical trials and integration of microbial, clinical and lifestyle data, we can move toward more targeted and effective interventions.”
The Open up for Innovation conference offered Chinmay Dwibedi and all other participants excellent opportunities to network.
ImageTomas RuuthHe also noted the Open up for Innovation event for its inspiring atmosphere and ambitions.
“It was great to hear about the region’s strategic focus on investment and translational science. And it was clearly valuable for doctoral students exploring opportunities beyond academia.”
